Skip to main content
Erschienen in: Annals of Surgical Oncology 2/2022

14.09.2021 | Hepatobiliary Tumors

Preventing Futile Liver Resection: A Risk-Based Approach to Surgical Selection in Major Hepatectomy for Colorectal Cancer

verfasst von: Marc W. Fromer, MD, Charles R. Scoggins, MD, MBA, Michael E. Egger, MD, MPH, Prejesh Philips, MD, Kelly M. McMasters, MD, PhD, Robert C. G. Martin II, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Early recurrence following liver resection for metastatic colorectal cancer generally portends poor survival. We sought to identify factors associated with early disease recurrence after major hepatectomy for metastatic colorectal cancer in order to improve patient selection and prevent futile hepatectomy.

Methods

Sequential major (four or more segments) liver resections performed for metastatic colorectal cancer between 1995 and 2019 were selected from our prospectively maintained database. Univariate analyses, multivariable regression modelling, and survival analyses were used to identify predictors of futile resection (recurrence within 6 months of hepatectomy).

Results

Of 259 patients included, the median age was 61.3 years (interquartile range [IQR] 15.3) and the median number of liver tumors was 3.0 (IQR 2.0); 78.0% of patients received prehepatectomy chemotherapy. Surgeries were right (56.4%), left (19.3%), and extended hepatectomy (24.3%). Futile resection occurred in 26 (12.6%) patients. Margin positivity was similar in the futile resection group compared with the non-futile resection group (11.5% vs. 11.4%). Extrahepatic disease that disappeared with chemotherapy was present in 23.1% of patients with a futile resection and 7.2% of those without (p = 0.019). After multivariable regression, the factors predictive of futile resection were extrahepatic disease (odds ratio [OR] 5.6; p = 0.004), more than three liver lesions (OR 4.9; p = 0.001), and extended hepatectomy (OR 2.6; p = 0.038). Notably, 70.8% of futile recurrences occurred within the liver remnant and 20.8% were pulmonary metastases. Overall survival was 11.7 months (95% confidence interval [CI] 7.1–16.2) for the futile resection cohort versus 45.6 (95% CI 39.1–52.1) for non-futile hepatectomies (p < 0.001).

Conclusions

Futile hepatic resection can be predicted based on preoperative factors and carries a poor prognosis. Improved risk stratification for futility will aid in patient selection and treatment discussions.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.CrossRef
2.
Zurück zum Zitat Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14:810.CrossRef Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14:810.CrossRef
3.
Zurück zum Zitat Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–9.CrossRef Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–9.CrossRef
4.
Zurück zum Zitat Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 2007;109(4):718–26.CrossRef Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 2007;109(4):718–26.CrossRef
5.
Zurück zum Zitat Pulitano C, Castillo F, Aldrighetti L, Bodingbauer M, Parks RW, Ferla G, et al. What defines “cure” after liver resection for colorectal metastases? Results after 10 years of follow-up. HPB (Oxford). 2010;12(4):244–9.CrossRef Pulitano C, Castillo F, Aldrighetti L, Bodingbauer M, Parks RW, Ferla G, et al. What defines “cure” after liver resection for colorectal metastases? Results after 10 years of follow-up. HPB (Oxford). 2010;12(4):244–9.CrossRef
6.
Zurück zum Zitat Adam R, Yi B, Innominato PF, Barroso E, Laurent C, Giuliante F, et al. Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients. Eur J Cancer. 2017;78:7–15.CrossRef Adam R, Yi B, Innominato PF, Barroso E, Laurent C, Giuliante F, et al. Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients. Eur J Cancer. 2017;78:7–15.CrossRef
7.
Zurück zum Zitat Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH.(1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 230(3):309-318; discussion 318-321. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH.(1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 230(3):309-318; discussion 318-321.
8.
Zurück zum Zitat Hill CR, Chagpar RB, Callender GG, Brown RE, Gilbert JE, Martin RC 2nd, et al. recurrence following hepatectomy for metastatic colorectal cancer: development of a model that predicts patterns of recurrence and survival. Ann Surg Oncol. 2012;19(1):139–44.CrossRef Hill CR, Chagpar RB, Callender GG, Brown RE, Gilbert JE, Martin RC 2nd, et al. recurrence following hepatectomy for metastatic colorectal cancer: development of a model that predicts patterns of recurrence and survival. Ann Surg Oncol. 2012;19(1):139–44.CrossRef
9.
Zurück zum Zitat Chua TC, Saxena A, Chu F, Zhao J, Morris DL. Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5- and 10-year survivors. J Surg Oncol. 2011;103(8):796–800.CrossRef Chua TC, Saxena A, Chu F, Zhao J, Morris DL. Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5- and 10-year survivors. J Surg Oncol. 2011;103(8):796–800.CrossRef
10.
Zurück zum Zitat Tan MC, Butte JM, Gonen M, Kemeny N, Fong Y, Allen PJ, et al. Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis. HPB (Oxford). 2013;15(10):803–13.CrossRef Tan MC, Butte JM, Gonen M, Kemeny N, Fong Y, Allen PJ, et al. Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis. HPB (Oxford). 2013;15(10):803–13.CrossRef
11.
Zurück zum Zitat Bhogal RH, Hodson J, Bramhall SR, Isaac J, Marudanayagam R, Mirza DF, et al. Predictors of early recurrence after resection of colorectal liver metastases. World J Surg Oncol. 2015;13:135.CrossRef Bhogal RH, Hodson J, Bramhall SR, Isaac J, Marudanayagam R, Mirza DF, et al. Predictors of early recurrence after resection of colorectal liver metastases. World J Surg Oncol. 2015;13:135.CrossRef
12.
Zurück zum Zitat Kaibori M, Iwamoto Y, Ishizaki M, Matsui K, Yoshioka K, Asano H, et al. Predictors and outcome of early recurrence after resection of hepatic metastases from colorectal cancer. Langenbecks Arch Surg. 2012;397(3):373–81.CrossRef Kaibori M, Iwamoto Y, Ishizaki M, Matsui K, Yoshioka K, Asano H, et al. Predictors and outcome of early recurrence after resection of hepatic metastases from colorectal cancer. Langenbecks Arch Surg. 2012;397(3):373–81.CrossRef
13.
Zurück zum Zitat Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18(1):136–47.CrossRef Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18(1):136–47.CrossRef
14.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.CrossRef Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.CrossRef
15.
Zurück zum Zitat Neugut AI, Lin A, Raab GT, Hillyer GC, Keller D, O’Neil DS, et al. FOLFOX and FOLFIRI Use in Stage IV colon cancer: analysis of SEER-medicare data. Clin Colorectal Cancer. 2019;18(2):133–40.CrossRef Neugut AI, Lin A, Raab GT, Hillyer GC, Keller D, O’Neil DS, et al. FOLFOX and FOLFIRI Use in Stage IV colon cancer: analysis of SEER-medicare data. Clin Colorectal Cancer. 2019;18(2):133–40.CrossRef
16.
Zurück zum Zitat Vargas GM, Sheffield KM, Parmar AD, Han Y, Gajjar A, Brown KM, et al. Trends in treatment and survival in older patients presenting with stage IV colorectal cancer. J Gastrointest Surg. 2014;18(2):369–77.CrossRef Vargas GM, Sheffield KM, Parmar AD, Han Y, Gajjar A, Brown KM, et al. Trends in treatment and survival in older patients presenting with stage IV colorectal cancer. J Gastrointest Surg. 2014;18(2):369–77.CrossRef
17.
Zurück zum Zitat Tanaka T, Sato T, Nishiofuku H, Masada T, Tatsumoto S, Marugami N, et al. Selective TACE with irinotecan-loaded 40 mum microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study. BMC Cancer. 2019;19(1):758.CrossRef Tanaka T, Sato T, Nishiofuku H, Masada T, Tatsumoto S, Marugami N, et al. Selective TACE with irinotecan-loaded 40 mum microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study. BMC Cancer. 2019;19(1):758.CrossRef
18.
Zurück zum Zitat Wang LJ, Zhang ZY, Yan XL, Yang W, Yan K, Xing BC. Radiofrequency ablation versus resection for technically resectable colorectal liver metastasis: a propensity score analysis. World J Surg Oncol. 2018;16(1):207.CrossRef Wang LJ, Zhang ZY, Yan XL, Yang W, Yan K, Xing BC. Radiofrequency ablation versus resection for technically resectable colorectal liver metastasis: a propensity score analysis. World J Surg Oncol. 2018;16(1):207.CrossRef
19.
Zurück zum Zitat Martin RC 2nd, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121(20):3649–58.CrossRef Martin RC 2nd, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121(20):3649–58.CrossRef
20.
Zurück zum Zitat Matsuoka H, Morise Z, Tanaka C, Hayashi T, Ikeda Y, Maeda K, et al. Repeat hepatectomy with systemic chemotherapy might improve survival of recurrent liver metastasis from colorectal cancer-a retrospective observational study. World J Surg Oncol. 2019;17(1):33.CrossRef Matsuoka H, Morise Z, Tanaka C, Hayashi T, Ikeda Y, Maeda K, et al. Repeat hepatectomy with systemic chemotherapy might improve survival of recurrent liver metastasis from colorectal cancer-a retrospective observational study. World J Surg Oncol. 2019;17(1):33.CrossRef
21.
Zurück zum Zitat Wang SJ, Si XY, Cai ZB, Zhou YM. Survival after repeat hepatectomy for recurrent colorectal liver metastasis: a review and meta-analysis of prognostic factors. Hepatobiliary Pancreat Dis Int. 2019;18(4):313–20.CrossRef Wang SJ, Si XY, Cai ZB, Zhou YM. Survival after repeat hepatectomy for recurrent colorectal liver metastasis: a review and meta-analysis of prognostic factors. Hepatobiliary Pancreat Dis Int. 2019;18(4):313–20.CrossRef
22.
Zurück zum Zitat Wicherts DA, de Haas RJ, Salloum C, Andreani P, Pascal G, Sotirov D, et al. Repeat hepatectomy for recurrent colorectal metastases. Br J Surg. 2013;100(6):808–18.CrossRef Wicherts DA, de Haas RJ, Salloum C, Andreani P, Pascal G, Sotirov D, et al. Repeat hepatectomy for recurrent colorectal metastases. Br J Surg. 2013;100(6):808–18.CrossRef
23.
Zurück zum Zitat Fromer MW, Aloia TA, Gaughan JP, Atabek UM, Spitz FR. The utility of the MELD score in predicting mortality following liver resection for metastasis. Eur J Surg Oncol. 2016;42(10):1568–75.CrossRef Fromer MW, Aloia TA, Gaughan JP, Atabek UM, Spitz FR. The utility of the MELD score in predicting mortality following liver resection for metastasis. Eur J Surg Oncol. 2016;42(10):1568–75.CrossRef
24.
Zurück zum Zitat Kasai M, Cipriani F, Gayet B, Aldrighetti L, Ratti F, Sarmiento JM, et al. Laparoscopic versus open major hepatectomy: a systematic review and meta-analysis of individual patient data. Surgery. 2018;163(5):985–95.CrossRef Kasai M, Cipriani F, Gayet B, Aldrighetti L, Ratti F, Sarmiento JM, et al. Laparoscopic versus open major hepatectomy: a systematic review and meta-analysis of individual patient data. Surgery. 2018;163(5):985–95.CrossRef
25.
Zurück zum Zitat Imai K, Allard MA, Benitez CC, Vibert E, Sa Cunha A, Cherqui D, et al. Early recurrence after hepatectomy for colorectal liver metastases: what optimal definition and what predictive factors? Oncologist. 2016;21(7):887–94.CrossRef Imai K, Allard MA, Benitez CC, Vibert E, Sa Cunha A, Cherqui D, et al. Early recurrence after hepatectomy for colorectal liver metastases: what optimal definition and what predictive factors? Oncologist. 2016;21(7):887–94.CrossRef
26.
Zurück zum Zitat Malik HZ, Gomez D, Wong V, Al-Mukthar A, Toogood GJ, Lodge JP, et al. Predictors of early disease recurrence following hepatic resection for colorectal cancer metastasis. Eur J Surg Oncol. 2007;33(8):1003–9.CrossRef Malik HZ, Gomez D, Wong V, Al-Mukthar A, Toogood GJ, Lodge JP, et al. Predictors of early disease recurrence following hepatic resection for colorectal cancer metastasis. Eur J Surg Oncol. 2007;33(8):1003–9.CrossRef
27.
Zurück zum Zitat Lin J, Peng J, Zhao Y, Luo B, Zhao Y, Deng Y, et al. Early recurrence in patients undergoing curative resection of colorectal liver oligometastases: identification of its clinical characteristics, risk factors, and prognosis. J Cancer Res Clin Oncol. 2018;144(2):359–69.CrossRef Lin J, Peng J, Zhao Y, Luo B, Zhao Y, Deng Y, et al. Early recurrence in patients undergoing curative resection of colorectal liver oligometastases: identification of its clinical characteristics, risk factors, and prognosis. J Cancer Res Clin Oncol. 2018;144(2):359–69.CrossRef
28.
Zurück zum Zitat Takahashi S, Konishi M, Kinoshita T, Gotohda N, Kato Y, Saito N, et al. Predictors for early recurrence after hepatectomy for initially unresectable colorectal liver metastasis. J Gastrointest Surg. 2013;17(5):939–48.CrossRef Takahashi S, Konishi M, Kinoshita T, Gotohda N, Kato Y, Saito N, et al. Predictors for early recurrence after hepatectomy for initially unresectable colorectal liver metastasis. J Gastrointest Surg. 2013;17(5):939–48.CrossRef
29.
Zurück zum Zitat Takahashi S, Konishi M, Nakagohri T, Gotohda N, Saito N, Kinoshita T. Short time to recurrence after hepatic resection correlates with poor prognosis in colorectal hepatic metastasis. Jpn J Clin Oncol. 2006;36(6):368–75.CrossRef Takahashi S, Konishi M, Nakagohri T, Gotohda N, Saito N, Kinoshita T. Short time to recurrence after hepatic resection correlates with poor prognosis in colorectal hepatic metastasis. Jpn J Clin Oncol. 2006;36(6):368–75.CrossRef
Metadaten
Titel
Preventing Futile Liver Resection: A Risk-Based Approach to Surgical Selection in Major Hepatectomy for Colorectal Cancer
verfasst von
Marc W. Fromer, MD
Charles R. Scoggins, MD, MBA
Michael E. Egger, MD, MPH
Prejesh Philips, MD
Kelly M. McMasters, MD, PhD
Robert C. G. Martin II, MD, PhD
Publikationsdatum
14.09.2021
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2022
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-021-10761-0

Weitere Artikel der Ausgabe 2/2022

Annals of Surgical Oncology 2/2022 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.